Literature DB >> 30592659

Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome.

Dunbar Ivy1,2, Neil Wilson1,2.   

Abstract

Entities:  

Keywords:  Editorials; Eisenmenger syndrome; congenital heart disease; endothelin receptor antagonist; pulmonary hypertension

Mesh：

Substances：

Year:  2019        PMID： 30592659      PMCID： PMC6364313          DOI： 10.1161/CIRCULATIONAHA.118.037171

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

1.  The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt.

Authors:  P WOOD
Journal:  Br Med J       Date:  1958-09-27

2.  Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.

Authors:  Nazzareno Galiè; Maurice Beghetti; Michael A Gatzoulis; John Granton; Rolf M F Berger; Andrea Lauer; Eleonora Chiossi; Michael Landzberg
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension.

Authors:  Konstantinos Dimopoulos; Ryo Inuzuka; Sara Goletto; Georgios Giannakoulas; Lorna Swan; Stephen J Wort; Michael A Gatzoulis
Journal:  Circulation       Date:  2009-12-21       Impact factor: 29.690

5.  Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977-2012.

Authors:  Cristel Sørensen Hjortshøj; Annette Schophuus Jensen; Keld Sørensen; Edit Nagy; Bengt Johansson; Thomas Kronvall; Mikael Dellborg; Mette-Elise Estensen; Henrik Holmstrøm; Maila Turanlahti; Ulf Thilén; Lars Søndergaard
Journal:  Heart       Date:  2017-04-27       Impact factor: 5.994

6.  Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.

Authors:  Alessandra Manes; Massimiliano Palazzini; Enri Leci; Maria L Bacchi Reggiani; Angelo Branzi; Nazzareno Galiè
Journal:  Eur Heart J       Date:  2013-03-01       Impact factor: 29.983

7.  Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.

Authors:  Maurice Beghetti; Andrzej Rudzinski; Min Zhang
Journal:  BMC Cardiovasc Disord       Date:  2017-07-04       Impact factor: 2.298
  7 in total
  2 in total

Review 1.  Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Authors:  Andreas Haryono; Risa Ramadhiani; Gusty Rizky Teguh Ryanto; Noriaki Emoto
Journal:  Biology (Basel)       Date:  2022-05-16

2.  Endothelin-1 Augments Therapeutic Potency of Human Mesenchymal Stem Cells via CDH2 and VEGF Signaling.

Authors:  Eun Ju Lee; Injoo Hwang; Gi-Hwan Kim; Dodam Moon; Su Yeon Kang; In-Chang Hwang; Seo-Yeon Lee; P J Marie; Hyo-Soo Kim
Journal:  Mol Ther Methods Clin Dev       Date:  2019-05-17       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.